ProMIS Neurosciences Inc PMN

Valuation/ Ray Blanco

[goldtech]

I find this to be a funny valuation when in fact the stock traded in the 70 cent range when Ray Blanco gave it a thumbs up. If you take the 60 to 1 rollback it's 42 dollars. What is the market cap of a drug with no aria E and the best in class.

[FarmerBetsy]

Yes, they really have not had any analyst coverage compared to other companies. Limited to two companies in the past couple of years. One of them Argus Research paid for by Promis. Sums it up. What they have had has always been wrong. The other Lede Jones Gable who published on May 26th a target of $26. and again published on July 18th a target of $26 available on Cantech. We know what happened

[Gbathat]

I'd guess $15-20B at the end of Ph2 if the data shows significant improvement in activity and no ARIA-E.  I think it could approach $2B with good Phase 1b readouts showing no ARIA plus good biomarker data.  At that point, a buyout would be likely, imo. I think the lack of ARIA-E could be a game changer that could blow away the competition.  Given the choice between one drug

[FarmerBetsy]

Value after phase 1, most if not all big pharma names pass phase 1 safety profile testing in Alzheimers trials. Latest trials Prothena and Acumen who started two years ago with their first testing patient announced good safety profile  results this summer with a low rate of Aria-e. Didn't see their market value increase 2 billion or any other Pharma. Promis acknowledges they might have

[Gbathat]

From our July press release, which briefly catapulted the stock: Additionally, of all antibodies tested including biosimilars for ACU193 and PRX012, only PMN310 and solanezumab did not bind to plaque, potentially reducing the incidence of Aβ-related imaging abnormalities (ARIA) associated with plaque-binding antibodies.

[G1945V]

FarmerBetsy, your point is what, in all of this? G1945V